{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE330nnn/GSE330958/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330958"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Leveraging TNFR2 for antitumour immunity: Treg depletion and myeloid reprogramming versus T cell costimulation","description":"We conducted single-cell RNA sequencing using the 10x Genomics Chromium Next-GEM Flex protocol to investigate the mechanism of action of two TNFR2-targeting antibodies—one ligand-blocking and the other agonistic. Our goal was to assess their anti-cancer potential in comparison to established immune checkpoint inhibitors, anti-PD1 and anti-CTLA4. These studies provide new insights and role of TNFR2 as a therapeutic target in cancer.","dates":{"publication":"2026/07/09"},"accession":"GSE330958","cross_references":{"GSM":["GSM9736509","GSM9736507","GSM9736508","GSM9736516","GSM9736517","GSM9736514","GSM9736515","GSM9736512","GSM9736513","GSM9736510","GSM9736511"],"GPL":["24247"],"GSE":["330958"],"taxon":["Mus musculus"],"PMID":["[42466984]"]}}